Amarin Pharma, Inc.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2013–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	2	1
2024	—	4	1
2022	—	1	1
2021	—	4	1
2020	—	4	1
2019	—	5	1
2018	—	4	1
2017	—	4	1
2016	—	5	1
2015	—	5	2
2014	—	8	2
2013	—	4	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
KING & SPALDING LLP	—	43
COVINGTON & BURLING LLP	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	37
SENATE	37
Natl Institutes of Health (NIH)	8
Centers For Medicare and Medicaid Services (CMS)	2
White House Office	2
Health & Human Services, Dept of (HHS)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	39
Insurance	Insurance	2

Bills Explicitly Cited (6)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6395117th Congress

No Mandates Act

2021 · first_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S. 4049/H.R. 6395)

Client expense: — · Firm income: $70,000

Matched citations: H.R. 6395

S. 4049117th Congress

Oversight to Lower Oil Prices Act

2021 · first_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S. 4049/H.R. 6395)

Client expense: — · Firm income: $70,000

Matched citations: S. 4049

H.R. 6395116th Congress

William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021

2020 · fourth_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S.4049/H.R.6395)

Client expense: — · Firm income: $80,000

Matched citations: H.R.6395

S. 4049116th Congress

National Defense Authorization Act for Fiscal Year 2021

2020 · fourth_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S.4049/H.R.6395)

Client expense: — · Firm income: $80,000

Matched citations: S.4049

Show 2 more cited filings

H.R. 6395116th Congress

William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021

2020 · third_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S.4049/H.R.6395)

Client expense: — · Firm income: $80,000

Matched citations: H.R.6395

S. 4049116th Congress

National Defense Authorization Act for Fiscal Year 2021

2020 · third_quarter · Firm: KING & SPALDING LLP

Open original LDA filing ↗

Cited source text and reported amounts

Advocacy related to cardiovascular health and reduction of residual risk after statins; National Defense Authorization Act for Fiscal Year 2021 (S.4049/H.R.6395)

Client expense: — · Firm income: $80,000

Matched citations: S.4049

Source: Senate LDA

Amarin Pharma, Inc. — Lobbying Disclosure | Poliscope